Tardive Dyskinesia Across Psychiatric Disorders

Download All
Access these interactive, online programs designed to provide the care team with the resources and practical guidance they need to apply the most recent data, guidelines, and expert recommendations for the personalized treatment of their patients with tardive dyskinesia.
Rif S. El-Mallakh, MD
Sanjay Gupta, MD
Greg W. Mattingly, MD
Joseph P. McEvoy, MD
Jonathan M. Meyer, MD
person default
Martha Sajatovic, MD


The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.

Joseph P. McEvoy, MD Released: May 4, 2021

Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.

Rif S. El-Mallakh, MD Released: June 8, 2021

Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.

Jonathan M. Meyer, MD Released: July 8, 2021

Tardive dyskinesia (TD) has a real-world impact on patient lives. Greg Mattingly, MD, explores the social and emotional impact of TD on patients as well as its prevalence and diagnosis.

Greg W. Mattingly, MD Released: September 27, 2021

The availability of 2 FDA-approved agents for the treatment of tardive dyskinesia has been a tremendous accomplishment. In this ClinicalThought, I explore the choices of FDA-approved agents to treat tardive dyskinesia and review what to consider.

Sanjay Gupta, MD Released: November 19, 2021

The burden of schizophrenia and tardive dyskinesia is extensive. In this expert commentary, Martha Sajatovic, MD, explores the American Psychiatric Association 2021 practice guidelines on tardive dyskinesia management in schizophrenia and the advancements in pharmacologic and psychosocial treatments.

person default Martha Sajatovic, MD Released: February 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings